Francesco Siracusa

Francesco Siracusa

Auto-generated profile, based on publicly available information

Francesco Siracusa

University Medical Center Hamburg-Eppendorf

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2018 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
AMAlessio Mazzoni
Alessio Mazzoni
LMLaura Maggi
Laura Maggi
FSFrancesco Siracusa
Francesco Siracusa
MRMatteo Ramazzotti
Matteo Ramazzotti
MRMaria Caterina Rossi
Maria Caterina Rossi
FAFrancesco Annunziato
Francesco Annunziato

14 August 2023 in Nature Immunology
Verified
Journal Article
Open access
PDF file
FSFrancesco Siracusa
Francesco Siracusa
NSNicola Schaltenberg
Nicola Schaltenberg
YKYogesh Kumar
Yogesh Kumar
TLTill R. Lesker
Till R. Lesker
BSBabett Steglich
Babett Steglich
NGNicola Gagliani
Nicola Gagliani
Omnivorous animals, including mice and humans, tend to prefer energy-dense nutrients rich in fat over plant-based diets, especially for short periods of time, but the health consequences of this short-term consumption of energy-dense nutrients are unclear. Here, we show that short-term reiterative switching to ‘feast diets’, mimicking our social eating behavior, breaches the potential buffering effect of the intestinal microbiota and reorganizes the immunological architecture of mucosa-associated lymphoid tissues. The first dietary switch was sufficient to induce transient mucosal immune depression and suppress systemic immunity, leading to higher susceptibility to Salmonella enterica serovar Typhimurium and Listeria monocytogenes infections. The ability to respond to antigenic challenges with a model antigen was also impaired. These observations could be explained by a reduction of CD4+ T cell metabolic fitness and cytokine production due to impaired mTOR activity in response to reduced microbial provision of fiber metabolites. Reintroducing dietary fiber rewired T cell metabolism and restored mucosal and systemic CD4+ T cell functions and immunity. Finally, dietary intervention with human volunteers confirmed the effect of short-term dietary switches on human CD4+ T cell functionality. Therefore, short-term nutritional changes cause a transient depression of mucosal and systemic immunity, creating a window of opportunity for pathogenic infection.

11 February 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
JRJulia K. Rohde
Julia K. Rohde
MFManka Fuh
Manka Fuh
IEIoannis Evangelakos
Ioannis Evangelakos
MPMira J. Pauly
Mira J. Pauly
NSNicola Schaltenberg
Nicola Schaltenberg
AWAnna Worthmann
Anna Worthmann
Short Chain Fatty Acids (SCFAs) are produced by the gut microbiota and are present in varying concentrations in the intestinal lumen, in feces but also in the circulatory system. By interacting with different cell types in the body, they have a great impact on host metabolism and their exact quantification is indispensable. Here, we present a derivatization-free method for the gas chromatography mass spectrometry (GC-MS) based quantification of SCFAs in plasma, feces, cecum, liver and adipose tissue. SCFAs were extracted using ethanol and concentrated by alkaline vacuum centrifugation. To allow volatility for separation by GC, samples were acidified with succinic acid. Analytes were detected in selected ion monitoring (SIM) mode and quantified using deuterated internal standards and external calibration curves. Method validation rendered excellent linearity (R2 > 0.99 for most analytes), good recovery rates (95–117%), and good reproducibility (RSD: 1–4.5%). Matrix effects were ruled out in plasma, feces, cecum, liver and fat tissues where most abundant SCFAs were detected and accurately quantified. Finally, applicability of the method was assessed using samples derived from conventionally raised versus germ-free mice or mice treated with antibiotics. Altogether, a reliable, fast, derivatization-free GC-MS method for the quantification of SCFAs in different biological matrices was developed allowing for the study of the (patho)physiological role of SCFAs in metabolic health.

22 January 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
FSFrancesco Siracusa
Francesco Siracusa
MMMairi A. McGrath
Mairi A. McGrath
PMPatrick Maschmeyer
Patrick Maschmeyer
MBMarkus Bardua
Markus Bardua
KLKatrin Lehmann
Katrin Lehmann
ARAndreas Radbruch
Andreas Radbruch
The bone marrow maintains memory CD4 T cells, which provide memory to systemic antigens. Here we demonstrate that memory CD4 T cells are reactivated by antigen in the bone marrow. In a secondary immune response, antigen-specific T cells of the bone marrow mobilize and aggregate in immune clusters together with MHC class II-expressing cells, mostly B lymphocytes. They proliferate vigorously and express effector cytokines, but they do not develop into follicular T-helper cells. Neither do the B lymphocytes develop into germinal center B cells in the bone marrow. Within 10 days, the immune clusters disappear again. Within 30 days, the expanded antigen-specific memory CD4 T cells return to memory niches and are maintained again individually as resting cells. Thus, in secondary immune responses in the bone marrow T-cell memory is amplified, while in germinal center reactions of secondary lymphoid organs humoral memory is adapted by affinity maturation.

16 August 2017 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
FSFrancesco Siracusa
Francesco Siracusa
ÖAÖzen Sercan Alp
Özen Sercan Alp
PMPatrick Maschmeyer
Patrick Maschmeyer
MMMairi McGrath
Mairi McGrath
MMMir-Farzin Mashreghi
Mir-Farzin Mashreghi
ARAndreas Radbruch
Andreas Radbruch
It is current belief that numbers of CD8+ memory T lymphocytes in the memory phase of an immune response are maintained by homeostatic proliferation. Here, we compare the proliferation of CD8+ memory T lymphocytes, generated by natural infections and by intentional immunization, in spleen and bone marrow (BM). Fifty percent of CD8+ memory T lymphocytes in the spleen are eliminated by cyclophosphamide within 14 days, indicating that numbers of at least 50% of splenic CD8+ memory T lymphocytes are maintained by proliferation. The numbers of CD8+ memory T lymphocytes in the BM, however, were not affected by cyclophosphamide. This stability was independent of circulating CD8+ memory T cells, blocked by FTY720, showing that BM is a privileged site for the maintenance of memory T lymphocytes, as resident cells, resting in terms of proliferation.

1 May 2018 in Journal of Autoimmunity
Verified
Journal Article
Open access
PMPatrick Maschmeyer
Patrick Maschmeyer
GPGeorg Petkau
Georg Petkau
FSFrancesco Siracusa
Francesco Siracusa
JZJakob Zimmermann
Jakob Zimmermann
FZFranziska Zügel
Franziska Zügel
MMMir-Farzin Mashreghi
Mir-Farzin Mashreghi
In T lymphocytes, expression of miR-148a is induced by T-bet and Twist1, and is specific for pro inflammatory Th1 cells. In these cells, miR-148a inhibits the expression of the pro-apoptotic protein Bim and promotes their survival. Here we use sequence-specific cholesterol-modified oligonucleotides against miR-148a (antagomir-148a) for the selective elimination of pro-inflammatory Th1 cells in vivo. In the murine model of transfer colitis, antagomir-148a treatment reduced the number of pro-inflammatory Th1 cells in the colon of colitic mice by 50% and inhibited miR-148a expression by 71% in the remaining Th1 cells. Expression of Bim protein in colonic Th1 cells was increased. Antagomir-148a-mediated reduction of Th1 cells resulted in a significant amelioration of colitis. The effect of antagomir-148a was selective for chronic inflammation. Antigen-specific memory Th cells that were generated by an acute immune reaction to nitrophenylacetyl-coupled chicken gamma globulin (NP-CGG) were not affected by treatment with antagomir-148a, both during the effector and the memory phase. In addition, antibody titers to NP-CGG were not altered. Thus, antagomir-148a might qualify as an effective drug to selectively deplete pro-inflammatory Th1 cells of chronic inflammation without affecting the protective immunological memory. (C) 2017 The Authors. Published by Elsevier Ltd.